PT-141 (Bremelanotide): Dosage, Protocol, and Reconstitution Guide

Bremelanotide (PT-141)

Bremelanotide, also known as PT-141, is a melanocortin receptor agonist studied and prescribed for female sexual desire disorders. It works centrally rather than through direct vascular effects, which makes it distinct from PDE5-style medications.

Important Distinction

Bremelanotide (PT-141) is NOT a tanning peptide.

It does not work like Melanotan II and is not used for skin pigmentation.

Although both act on melanocortin receptors, PT-141 primarily affects the central nervous system.

How It Works

Melanocortin Receptor Activation → Dopamine Signaling ↑ → Sexual Desire / Arousal Support ↑

Bremelanotide activates melanocortin receptors in the central nervous system, especially MC4R-related pathways involved in sexual desire and response. It is used on demand rather than as a daily therapy.

Bremelanotide Protocol

Standard On-Demand Use

Dose1.75 mg

Units35 units

TimingAt least 45 min before activity

FrequencyAs needed

Maximum: No more than 1 dose in 24 hours
Monthly Limit: No more than 8 doses per month
Reassessment: Discontinue after 8 weeks if no meaningful benefit

Advanced / Educational Vial Conversion

Equivalent Dose Using Vial Example

Target Dose1.75 mg

Units35 units (0.35 mL)

This section is only for consistency with your site format. Official branded product is supplied as a prefilled autoinjector rather than a reconstituted vial.

When & Where to Inject

• Subcutaneous injection
• Abdomen or thigh are standard sites
• Use at least 45 minutes before anticipated activity
• Do not repeat within the same 24-hour period

Reconstitution & Dosing (10 mg Vial)

Vial 10 mg

Water 2.0 mL

Concentration 5 mg/mL

Conversion 1 unit = 50 mcg

Reconstitution Steps

Draw 2.0 mL bacteriostatic water

Inject slowly down vial wall

Gently swirl (do not shake)

Refrigerate immediately

Storage

Lyophilized: refrigerated or frozen

Reconstituted: 2–8°C

Use Window

Use within ~30 days

Monitoring During Use

• Nausea or flushing after injection
• Blood pressure response
• Injection site tolerance
• Whether meaningful benefit occurs within 8 weeks

Benefits

• On-demand use rather than daily dosing
• Central mechanism different from PDE5 medications
• May improve sexual desire and related distress
• Convenient single-use dosing format in official product

Potential Side Effects

• Nausea
• Flushing
• Injection site reactions
• Headache
• Transient blood pressure increase
• Possible skin hyperpigmentation with repeated use

Stacking Strategies

• Use Caution: Avoid layering with other agents that may worsen nausea or blood pressure changes
• Not a Typical Stack Peptide: Usually used standalone on demand
• Lifestyle Support: Pair with sleep, stress reduction, and relationship-focused interventions where appropriate

Important Notes

• Official indication is for acquired, generalized HSDD in premenopausal women
• Not recommended in uncontrolled hypertension or known cardiovascular disease
• Official product is a prefilled autoinjector, not a vial
• Stop after 8 weeks if there is no improvement

Important Disclaimer

Bremelanotide is an FDA-approved prescription medication in branded form, but any non-branded vial-based use should be approached cautiously. This content is for educational purposes only.

Peptide Directory →